Siglec‐15 promotes the migration of liver cancer cells by repressing lysosomal degradation of CD44

ST6GAL2 Downregulation Inhibits Cell Adhesion and Invasion and is Associated with Improved Patient Survival in Breast Cancer

(2020) Junchi Cheng et al.   OncoTargets and Therapy

Targeting glycosylated antigens on cancer cells using siglec‐7/9‐based CAR T‐cells

(2020) Sara Meril et al.   MOLECULAR CARCINOGENESIS

Siglec-15 as an emerging target for next-generation cancer immunotherapy

(2020) Jingwei Sun et al.   CLINICAL CANCER RESEARCH

A versatile soluble siglec scaffold for sensitive and quantitative detection of glycan ligands

(2020) Emily Rodrigues et al.   Nature Communications

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

(2019) Jun Wang et al.   NATURE MEDICINE

Sialic acid–binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses

(2019) Heinz Läubli et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer

(2019) Lichun Ma et al.   CANCER CELL

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

Immune checkpoint therapy in liver cancer

(2018) Feng Xu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The biology and role of CD44 in cancer progression: therapeutic implications

(2018) Chen Chen et al.   Journal of Hematology & Oncology

Cell-based glycan arrays for probing glycan–glycan binding protein interactions

(2018) Jennie Grace Briard et al.   Nature Communications

CD44 Orchestrates Metastatic Teamwork

(2018) Christine L. Chaffer et al.   DEVELOPMENTAL CELL

DNMT3L facilitates DNA methylation partly by maintaining DNMT3A stability in mouse embryonic stem cells

(2018) Nicolas Veland et al.   NUCLEIC ACIDS RESEARCH

Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models

(2018) Xia Liu et al.   Cancer Discovery

Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions

(2018) Joyce Lübbers et al.   Frontiers in Immunology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

(2015) A. Ribas   Cancer Discovery

CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance

(2014) L. Nitschke   GLYCOBIOLOGY

Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells

(2013) Y. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-  secretion from monocytes/macrophages through the DAP12-Syk pathway

(2012) R. Takamiya et al.   GLYCOBIOLOGY

Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation

(2011) Yoshiharu Hiruma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Toward a stem cell gene therapy for breast cancer

(2009) Z. Li et al.   BLOOD